Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node"targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
| 4.85 | |
| 4.9 | |
| - | |
| 4.99 | |
| 4.78 | |
| 2.96-11.45 | |
| 50 513 K | |
| 10 770 K | |
| 0 | |
| -1.15 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at AACR Special Conference: Pancreatic CancerELI-002 2P induced T cell responses correlated wit...
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% (20/23) had direct ex vi...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
